

Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa.
27-29 June 2023

United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Presentation of opportunities for investment and partnerships on vaccines and biopharmaceuticals.

A. Who we are, & what we do

Please provide information on the company, its current portfolio, focus, specialization, and capacity.

Who we are:

Univercells is a global life sciences company that makes biologics available to all. Univercells develops breakthrough technologies and services that democratize the production of biologics. So that everyone, everywhere, has access to the medicines they need when they need them.

What we do:

We develop and design biomanufacturing technology and processes to make biologics easier and cheaper to produce thanks to our engineering approach.

We work with innovators to provide them with access to our production capacity and support emerging players in setting up their facilities. Not only do our partners have access to our cutting-edge manufacturing facilities in Belgium, but we can also help them establish their own bioproduction facilities. Our aim is to support the creation of a globally distributed manufacturing network.

We provide access to expertise in bioproduction, both services and advisory. Our team of experts works with academic institutions, government agencies, partners and clients around the world to support efforts around workforce development and training, as well as regulatory affairs; helping build biomanufacturing expertise and supporting production autonomy.

Some numbers:

- *Number of staff: 546*
- *Nationalities: 41*
- *Gender split: Female 43% / Male 57%*
- *Number of affiliates: 5*
- *Number of sites: 7*
- *Projects and product use in 29 countries*
- *17 projects running at our facilities*
- *52 investigative medicinal products supported*

B. What are we offering

Please provide information on what your company can provide to other partners, such as opportunities for partnership, technology license, training, feasibility study etc?

Based on our core expertise in bioprocess design and development, we develop breakthrough technologies and services that democratize the production of biologics. We are an expanding campus of interconnected business models; each solving a different part of the same puzzle - how to meet the global demand for bioproduction:

1. *Production systems:*

- *Cutting-edge, scalable technology portfolio to enable partners to achieve low cost, low footprint, high quality and high-performance production*
- *Applications in viral production, RNA and DNA from R&D to commercial*

2. *Research partnership to manufacturing (CDMO):*

- *Designing and operating bespoke bioproduction hubs with state-of-the-art technology*
- *From discovery to commercial cGMP capabilities and expertise for therapy innovators in C>, vaccines, DNA/RNA*

3. *Advisory: support governments and industrial players to boost their biomanufacturing ecosystem through a set of offering from design to operations of bioproduction sites, incl. tech transfer, training, and regulatory affairs.*

C. What are we looking for

Please provide information on what the company seeks from other partners (businesses, finance, and technology providers)?

Univercells (represented by its affiliate, Unizima) is looking for:

- *Present Unizima's business model for vaccines, insulin and other biologics Fill & Finish investment in Africa, including a detailed financial model that will be presented during Workshop 1 on day 3.*
- *Present Unizima's turnkey services/products to create biologics manufacturing on the African continent.*
- *Present Unizima's recruitment and biomanufacturing training services, leveraging how we operate our own factory and HR needs and tailored to the needs of our partners and clients in Africa.*
- *Meet/follow up with African pharma & biotech companies willing to invest in biologics manufacturing and discuss how Unizima can support their projects.*
- *Meet with vaccine producers interested to supply vaccine bulks for local Fill & Finish and discuss how they could match the current demands from African pharma & biotech companies.*

- *Meet with banks/investors for advice on how they can bring financial support to the African biologics manufacturing' projects at their different stages.*
- *Meet with supranational/government officials to advise on how they can sponsor African biologics manufacturing projects, support workforce development, and foster the creation of an ecosystem.*
- *Meet with innovation partners across viral vectors, nucleic acid, car-t, cell-free protein synthesis, mAbs,...to unleash the potential of the next vaccines and therapeutics.*
- *Meet complementary partners to strengthen distributed manufacturing for pandemic preparedness (governments, academia, clusters, biopharma/biotech - vaccines and therapeutics).*
- *Meet potential co-developer of vaccines of global health interest.*
- *Meet biotech/biopharma looking for a hosting facility at the heart of Europe in the Wallonian leading ecosystem.*

Contact:

Unizima: hello@unizima.com

Hala AUDI, Unizima CEO: h.audi@unizima.com

Benoit GREGOIRE, Unizima BD Manager & Sr Tech Transfer Expert: b.gregoire@unizima.com

Nick NTAHOKAJA, Unizima Sr Strategic Advisor Africa: n.ntahokaja@unizima.com

Johnny VLAMINCK, Unizima BD Manager & Licensing Expert: j.vlaminck@unizima.com

Website:

www.unizima.com